Human hepatitis B immunoglobulin (pH4, Wuhan Institute Of Biological Products)
乙型肝炎人免疫球蛋白（ph4，武汉生物制品研究所）
Report date: 2022/01/14 13:23:58
Base Information
Drug NameHuman hepatitis B immunoglobulin (pH4, Wuhan Institute Of Biological Products)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesWuhan Institute Of Biological Products Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesWuhan Institute Of Biological Products Co Ltd
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A